ARK Genomic Revolution ETF $ARKG Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut its stake in ARK Genomic Revolution ETF (BATS:ARKG) by 9.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,943,913 shares of the company’s stock after selling 410,039 shares during the period. JPMorgan Chase & Co. owned 8.82% of ARK Genomic Revolution ETF worth $109,522,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Jaffetilchin Investment Partners LLC bought a new stake in shares of ARK Genomic Revolution ETF in the 2nd quarter worth about $994,000. Next Capital Management LLC bought a new position in ARK Genomic Revolution ETF during the 2nd quarter worth approximately $318,000. Simplex Trading LLC acquired a new position in shares of ARK Genomic Revolution ETF in the 2nd quarter worth approximately $936,000. D.A. Davidson & CO. bought a new stake in shares of ARK Genomic Revolution ETF in the 3rd quarter valued at approximately $1,392,000. Finally, NTV Asset Management LLC bought a new stake in shares of ARK Genomic Revolution ETF in the 3rd quarter valued at approximately $4,449,000.

ARK Genomic Revolution ETF Stock Performance

Shares of ARKG opened at $28.81 on Monday. The business’s fifty day moving average price is $30.28 and its 200 day moving average price is $28.91. ARK Genomic Revolution ETF has a 12-month low of $17.50 and a 12-month high of $34.39.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.